<p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）在週三發佈給投資者的報告中，被 StockNews.com 的研究分析師將評級從 “強力買入” 下調至 “買入”。</p>
<p>另外，Cantor Fitzgerald 在 2 月 27 日（星期四）的一份研究報告中重申了對 MiMedx Group 的 “增持” 評級，並給出了 13.00 美元的目標價。</p>
<p><strong>查看我們關於 MiMedx Group 的最新股票報告</strong></p>
<h2>MiMedx Group 股票表現</h2>
<p>在週三的交易中，納斯達克 MDXG 下跌 0.17 美元，報 6.63 美元。該公司股票交易量為 489,764 股，低於其平均交易量 696,177 股。該股票的市值為 9.7704 億美元，市盈率為 12.05，貝塔值為 1.74。該公司的 50 日移動平均價格為 7.75 美元，200 日移動平均價格為 7.99 美元。MiMedx Group 的 52 周低點為 5.47 美元，52 周高點為 10.14 美元。該公司的債務與股本比率為 0.10，流動比率為 4.10，速動比率為 3.53。</p>
<p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）最近在 2 月 26 日（星期三）發佈了季度財報。該公司報告每股收益為 0.07 美元，符合市場共識預期的 0.07 美元。MiMedx Group 的淨利潤率為 23.86%，股本回報率為 26.21%。該公司在本季度的收入為 9291 萬美元，而分析師預期為 8942 萬美元。賣方分析師預測 MiMedx Group 在當前財年將發佈 0.3 美元的每股收益。</p>
<h2>MiMedx Group 內部買賣情況</h2>
<p>在其他新聞中，首席會計官 William Frank Iv Hulse 於 3 月 10 日（星期一）出售了 81,446 股 MiMedx Group 的股票。該股票以平均價格 7.80 美元出售，總交易額為 635,278.80 美元。出售完成後，首席會計官現在持有 494,774 股公司股票，價值約為 3,859,237.20 美元。此交易代表其持股比例下降了 14.13%。該出售在向 SEC 的法律文件中披露，您可以通過此鏈接訪問。此外，內部人士 Kimberly Maersk-Moller 於 3 月 13 日（星期四）出售了 4,106 股該股票。該股票以平均價格 7.89 美元出售，總價值為 32,396.34 美元。交易完成後，內部人士現在持有 310,836 股公司股票，價值為 2,452,496.04 美元。此交易代表其持股比例下降了 1.30%。該出售的披露信息可以在這裏找到。在過去的 90 天裏，內部人士總共出售了 144,018 股公司股票，價值為 1,130,312 美元。目前，1.30% 的股票由公司內部人士持有。</p>
<h2>MiMedx Group 的機構交易</h2>
<p>幾家大型投資者最近買入和賣出了該公司的股票。Paradigm Capital Management Inc. NY 在第四季度增持了 MiMedx Group 的股份，增幅為 0.5%。Paradigm Capital Management Inc. NY 現在持有 4,686,231 股公司股票，價值為 45,082,000 美元，此前在上個季度又購買了 22,131 股。Cannell Capital LLC 在第四季度增持了 MiMedx Group 的股份，增幅為 1.1%。Cannell Capital LLC 現在持有 3,639,545 股公司股票，價值為 35,012,000 美元，此前在上個季度又購買了 40,235 股。First Light Asset Management LLC 在第四季度購買了 MiMedx Group 的新股份，價值為 32,168,000 美元。Geode Capital Management LLC 在第三季度增持了 MiMedx Group 的股份，增幅為 1.6%。Geode Capital Management LLC 現在持有 2,794,358 股公司股票，價值為 16,518,000 美元，此前在上個季度又購買了 44,254 股。最後，Renaissance Technologies LLC 在第四季度增持了 MiMedx Group 的股份，增幅為 18.4%。Renaissance Technologies LLC 現在持有 1,804,557 股公司股票，價值為 17,360,000 美元，此前在此期間又購買了 280,327 股。79.15% 的股票由機構投資者持有。</p>
<h2>MiMedx Group 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>MiMedx Group, Inc 開發和分銷用於各個醫療保健領域的胎盤組織同種異體移植物。它利用其專利和專有的 PURION 工藝處理人類胎盤組織，以生產保留組織固有生物特性和調節蛋白的同種異體移植物。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 MiMedx Group</li>
<li>ETF 是否支付股息？您需要知道的事項</li>
<li>Viking Therapeutics 股票上漲但難以保持漲幅</li>
<li>三隻值得購買和持有的醫療保健股息股票</li>
<li>高通股票剛剛獲得新的買入評級——值得期待</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>Meta 股票在分析師下調目標價時仍具上漲潛力</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 MiMedx Group 嗎？</h2>
<p>在您考慮 MiMedx Group 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MiMedx Group 並不在名單上。</p>
<p>雖然 MiMedx Group 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MDXG

<p>StockNews.com 將 MiMedx Group (NASDAQ:MDXG) 的評級從 “強力買入” 下調至 “買入”。該股票交易價格下跌至 $6.63，市值為 $9.7704 億。MiMedx 報告每股收益為 $0.07，符合預期，收入為 $9291 萬，超出預測。內部交易活動包括首席會計官 William Hulse 和內部人士 Kimberly Maersk-Moller 的大量出售。機構投資者持有該股票的 79.15%，Paradigm Capital Management 和 Cannell Capital 的持股顯著增加</p>

<p>MiMedx Group (NASDAQ:MDXG - Get Free Report) was downgraded by research analysts at StockNews.com from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Wednesday.</p>
<div class="lb-trans"><p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）在週三發佈給投資者的報告中，被 StockNews.com 的研究分析師將評級從 “強力買入” 下調至 “買入”。</p>
</div><p>Separately, Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.</p>
<div class="lb-trans"><p>另外，Cantor Fitzgerald 在 2 月 27 日（星期四）的一份研究報告中重申了對 MiMedx Group 的 “增持” 評級，並給出了 13.00 美元的目標價。</p>
</div><p><strong>Check Out Our Latest Stock Report on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 MiMedx Group 的最新股票報告</strong></p>
</div><h2>MiMedx Group Stock Performance</h2>
<div class="lb-trans"><h2>MiMedx Group 股票表現</h2>
</div><p>NASDAQ MDXG traded down $0.17 during trading on Wednesday, reaching $6.63. 489,764 shares of the company's stock were exchanged, compared to its average volume of 696,177. The stock has a market capitalization of $977.04 million, a P/E ratio of 12.05 and a beta of 1.74. The business has a 50 day moving average price of $7.75 and a 200-day moving average price of $7.99. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.</p>
<div class="lb-trans"><p>在週三的交易中，納斯達克 MDXG 下跌 0.17 美元，報 6.63 美元。該公司股票交易量為 489,764 股，低於其平均交易量 696,177 股。該股票的市值為 9.7704 億美元，市盈率為 12.05，貝塔值為 1.74。該公司的 50 日移動平均價格為 7.75 美元，200 日移動平均價格為 7.99 美元。MiMedx Group 的 52 周低點為 5.47 美元，52 周高點為 10.14 美元。該公司的債務與股本比率為 0.10，流動比率為 4.10，速動比率為 3.53。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $92.91 million during the quarter, compared to analysts' expectations of $89.42 million. Sell-side analysts forecast that MiMedx Group will post 0.3 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）最近在 2 月 26 日（星期三）發佈了季度財報。該公司報告每股收益為 0.07 美元，符合市場共識預期的 0.07 美元。MiMedx Group 的淨利潤率為 23.86%，股本回報率為 26.21%。該公司在本季度的收入為 9291 萬美元，而分析師預期為 8942 萬美元。賣方分析師預測 MiMedx Group 在當前財年將發佈 0.3 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 內部買賣情況</h2>
</div><p>In other news, CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the sale, the chief accounting officer now owns 494,774 shares in the company, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 144,018 shares of company stock worth $1,130,312 over the last ninety days. 1.30% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席會計官 William Frank Iv Hulse 於 3 月 10 日（星期一）出售了 81,446 股 MiMedx Group 的股票。該股票以平均價格 7.80 美元出售，總交易額為 635,278.80 美元。出售完成後，首席會計官現在持有 494,774 股公司股票，價值約為 3,859,237.20 美元。此交易代表其持股比例下降了 14.13%。該出售在向 SEC 的法律文件中披露，您可以通過此鏈接訪問。此外，內部人士 Kimberly Maersk-Moller 於 3 月 13 日（星期四）出售了 4,106 股該股票。該股票以平均價格 7.89 美元出售，總價值為 32,396.34 美元。交易完成後，內部人士現在持有 310,836 股公司股票，價值為 2,452,496.04 美元。此交易代表其持股比例下降了 1.30%。該出售的披露信息可以在這裏找到。在過去的 90 天裏，內部人士總共出售了 144,018 股公司股票，價值為 1,130,312 美元。目前，1.30% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Trading of MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 的機構交易</h2>
</div><p>Several large investors have recently bought and sold shares of the company. Paradigm Capital Management Inc. NY lifted its holdings in shares of MiMedx Group by 0.5% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock valued at $45,082,000 after purchasing an additional 22,131 shares in the last quarter. Cannell Capital LLC grew its holdings in MiMedx Group by 1.1% during the 4th quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock valued at $35,012,000 after buying an additional 40,235 shares in the last quarter. First Light Asset Management LLC bought a new stake in MiMedx Group in the fourth quarter worth $32,168,000. Geode Capital Management LLC raised its position in shares of MiMedx Group by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company's stock valued at $16,518,000 after buying an additional 44,254 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of MiMedx Group by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock worth $17,360,000 after purchasing an additional 280,327 shares during the period. 79.15% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家大型投資者最近買入和賣出了該公司的股票。Paradigm Capital Management Inc. NY 在第四季度增持了 MiMedx Group 的股份，增幅為 0.5%。Paradigm Capital Management Inc. NY 現在持有 4,686,231 股公司股票，價值為 45,082,000 美元，此前在上個季度又購買了 22,131 股。Cannell Capital LLC 在第四季度增持了 MiMedx Group 的股份，增幅為 1.1%。Cannell Capital LLC 現在持有 3,639,545 股公司股票，價值為 35,012,000 美元，此前在上個季度又購買了 40,235 股。First Light Asset Management LLC 在第四季度購買了 MiMedx Group 的新股份，價值為 32,168,000 美元。Geode Capital Management LLC 在第三季度增持了 MiMedx Group 的股份，增幅為 1.6%。Geode Capital Management LLC 現在持有 2,794,358 股公司股票，價值為 16,518,000 美元，此前在上個季度又購買了 44,254 股。最後，Renaissance Technologies LLC 在第四季度增持了 MiMedx Group 的股份，增幅為 18.4%。Renaissance Technologies LLC 現在持有 1,804,557 股公司股票，價值為 17,360,000 美元，此前在此期間又購買了 280,327 股。79.15% 的股票由機構投資者持有。</p>
</div><h2>MiMedx Group Company Profile</h2>
<div class="lb-trans"><h2>MiMedx Group 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 開發和分銷用於各個醫療保健領域的胎盤組織同種異體移植物。它利用其專利和專有的 PURION 工藝處理人類胎盤組織，以生產保留組織固有生物特性和調節蛋白的同種異體移植物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Meta Stock Holds Upside Potential as Analysts Cut Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 MiMedx Group</li>
<li>ETF 是否支付股息？您需要知道的事項</li>
<li>Viking Therapeutics 股票上漲但難以保持漲幅</li>
<li>三隻值得購買和持有的醫療保健股息股票</li>
<li>高通股票剛剛獲得新的買入評級——值得期待</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>Meta 股票在分析師下調目標價時仍具上漲潛力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 MiMedx Group 嗎？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 MiMedx Group 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MiMedx Group 並不在名單上。</p>
</div><p>While MiMedx Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MiMedx Group 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

StockNews.com 將 MiMedx Group（NASDAQ:MDXG）的評級下調至買入